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Introduction: Gene therapy has shown promise in clinical trials for patients with
haemophilia, but patient preference studies have focused on factor replacement
treatments.
Aim: We conducted a discrete choice experiment (DCE) to investigate the relative
importance and differential preferences patients provide for gene therapy attributes.
Methods: We surveyed male adults with haemophilia in the United States recruited
from patient panels including the National Hemophilia Foundation Community Voices
in Research platform using an online survey over 4 months in 2020/21. Par-
ticipants indicated preferences for gene therapy attributes including dosing fre-
quency/durability, effect on annual bleeding, uncertainty related to side effects, impact
on daily activities, impact onmental health, and post-treatment requirements. The rel-
ative importance of each attribute was analysed overall and for subgroups based on
haemophilia type and severity.
Results:A total of 183males with haemophilia A (n= 120) or B (n= 63) were included.
Half (47%) had severe haemophilia; most (75%) wereWhite. Overall, participants gave
effect on bleeding rate the greatest relative importance (31%), followed by dose fre-
quency/durability (26%), uncertainty regarding safety issues (17%), and impact ondaily
activities (11%). Dose frequency/durability had the greatest importance for thosewith
haemophilia B (35%).
Conclusion: People with haemophilia prioritised reduced bleeding and treatment bur-
den; the former was more important in haemophilia A and the latter in haemophilia B,
followedby safety and impact ondaily life in thisDCEof gene therapy attributes. These
findings and differences can inform clinical and health policy decisions to improve
health equity for people with haemophilia.
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1 INTRODUCTION
Persistent bleeding and associated sequelae impose significant lim-
itations on the daily functionality, mental health, and quality of life
for people with moderate or severe haemophilia.1,2 Replacement
of coagulation factor VIII or IX prophylactically has been successful
in reducing bleeding, joint damage, and pain, but does not prevent
breakthrough bleeds and subsequent morbidity over the long-term.3,4
The logistical requirements of prophylactic factor replacement impose
a further burden of their own that can compromise adherence.5,6
In the pursuit of new treatment options, gene therapy has shown
promise in clinical trials for patients with haemophilia A or B, mak-
ing long-term functional remediation of haemophilia a potential
reality.7–9
The nature of haemophilia and its ongoing management place par-
ticular importance on the patient perspective in clinical and health
policy decision-making. The patient’s active participation and commit-
ment to treatment decisions are important variables in the ability of
therapeutic advances to further improve real-world outcomes.As such,
quantifiable patient preference information is applied in health tech-
nology assessments to inform estimation of quality-adjusted life-years
in the evaluation of treatment benefits.10–13
To date, patient preference studies in haemophilia have focused on
the attributes of factor replacement therapies, with preferences pre-
dominantly related to efficacy, inhibitor development, and treatment
administration.14–16 Few studies have attempted to quantify patient
preferences related to gene therapy attributes, and none of those
exploring this emerging area have applied a discrete choice experi-
ment design among patients with moderate or severe haemophilia A
or B.17,18
As the literature has understandably focused on factor replace-
ment therapies, we sought to quantify patient perspectives on
gene therapy treatment attributes. We conducted a discrete choice
experiment (DCE) to investigate the relative importance patients
assign to characteristics of a gene therapy and to better under-
stand differential treatment attribute preferences among people with
haemophilia.
2 MATERIALS AND METHODS
A DCE was conducted among adult males with moderate or severe
haemophilia A or B in the United States. Participants completed
the survey which was available online between November 2020
and February 2021. Patient sampling included assistance from the
National Hemophilia Foundation’s Community Voices in Research ini-
tiative (www.hemophilia.org/research/community-voices-in-research)
and via M3 Global Research haemophilia patient panels. Participants
had to be ≥18 years of age with moderate/severe haemophilia A or B
living in the United States and able to read written English. All par-
ticipants provided informed consent. The study protocol and materi-
als were reviewed and determined to be exempt by New England IRB
(since acquired byWCG IRB, www.wcgirb.com).
This study was conducted in accordance with best practices for
DCE applications in healthcare.19,20 The survey collected demographic
and clinical characteristics followed by the DCE instrument where
participants indicated their preferences between treatment attributes
consisting of different levels. Self-reported demographic and clinical
characteristics such as haemophilia treatment, bleeding, joint health,
and familiarity with gene therapy were included.
2.1 Attribute development
A targeted review of the literature was conducted to inform devel-
opment of the DCE instrument including haemophilia treatment
attributes, previouspatient preference studies inhaemophilia, andout-
comemeasures in gene therapy clinical trials. Themost commonly used
treatment attributes identified in the literature searchwere dosing fre-
quency, reduction of bleeds and time to stop a bleed, breakthrough
bleeds and risk, out-of-pocket costs, and other medication costs. Qual-
itative assessment of the draft DCE instrument included input from
an expert reference group of four patient advocates and three health-
care providers specialising in haemophiliamanagement.We conducted
semi-structured interviews with a small sample of patient advocates
and clinical experts in order to refine the survey concepts and lan-
guage. A pilot study was then conducted with a small sample of peo-
plewith haemophilia (n=14) to ascertain comprehension of the choice
set tasks, treatment attribute descriptions and levels, as well as the
overall survey language and usability. Based on the input and feed-
back from all contributors to the qualitative assessment, the final DCE
included gene therapy attributes included dosing frequency and dura-
bility, effect on annual bleeding rate, uncertainty related to side effects,
impact on daily activities, impact onmental health, and post-treatment
requirements (Table 1).
2.2 Statistical analysis
The primary objectives were to measure the relative importance given
to each gene therapy attribute and to infer participant preferences by
evaluating the magnitude and direction of their assessments of gene
therapy attributes and levels. Responses to the DCEwere used to gen-
erate preference coefficients for each level of each treatment attribute
using random parameters logit regressions, where preference weights
represented the relative contribution of the attribute level to the
value that participants assigned to an alternative.21 The attribute-level
coefficients were expressed as mean preference weights and stan-
dard deviations of the mean preference weights, each with 95% con-
fidence intervals (CIs). The relative importance of each attribute was
expressed using the within-attribute difference in preference weights
as a percentage of the total difference in preference weights across
all attributes. Descriptive summary of demographic and clinical char-
acteristics as well as statistical testing of the primary objectives was
performed for the total population and for subgroups of people with
haemophilia A or B andmoderate or severe haemophilia.
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TABLE 1 Gene therapy treatment attributes and scenario options
in the DCE
Dose frequency and durability
Administrationmultiple times per week
Administration every 1–4weeks
One-time treatment, 10-year durability then return to standard of care
at that time
One-time treatment, lifetime durability
Effect on overall annual bleeding rate
0 bleeds per year
1 bleed per year
3 bleeds per year
5 ormore bleeds per year
Uncertainty regarding short-term or long-term significant safety
issues
Very low risk of short-termOR long-term significant safety issue
Potential risk of short-term safety issue
Potential risk of long-term safety issue
Potential risk of short-termAND long-term significant safety issue
Impact on activity of daily life/physical activity
Freedom to undertake daily activities, travel, and physical activity
Some planning required to undertake daily activities, travel, and
physical activity
A lot of planning required to undertake daily activities, travel, and
physical activity
Transformative/mental health impact
Freedom from thinking andworrying about haemophilia or the
treatmentmost days
Thinking andworrying about haemophilia or the treatment some days
Thinking andworrying about haemophilia or the treatmentmost days
Post treatment, possibility to undergominor surgerywithout need for
factor therapy
Factor therapy generally NOT needed
Factor therapymay ormay not be needed, depending on the situation
Factor therapy always needed
Model goodness of fit was assessed using the likelihood ratio Chi
square test to determine whether including attribute-level variables
significantly improvedmodel fit (versus amodel without any attribute-
level variables) and to indicate whether one or more of the preference
weights could be expected to be different from zero. Coefficients for
the levels and covariates were generatedwith relevant statistical mea-
sures including pseudo r-squared, log likelihood test and the Akaike
information criterion. Conditional logit models were explored but due
to limitations such as scale and preference heterogeneity, other mod-
elling randomparameters logitwasusedas theprimarymethod toanal-
yse the data.22,23 Quality checks included dominant (Figure A1) and
repeated scenario tests to evaluate comprehension and consistency,
respectively alongside time to complete the survey to ensure no speed-
ers were included. No imputation of missing values was performed. All
analyses were conducted using STATA version 16.0 (www.stata.com).
3 RESULTS
A total of 183 people with haemophilia A (n = 120) or haemophilia
B (n = 63) completed the survey and were included in the analysis.
Approximately half (47%) of all participants had severe haemophilia.
All participants were male and the majority (75%) were White, with
a mean age of 39 years (Table 2). Half of all participants (53%)
were employed full-time, though the proportion of full-time employed
patients was higher among those with haemophilia A (60%) or moder-
ate haemophilia (61%) compared to those with haemophilia B (38%)
or severe haemophilia (43%). Patients with haemophilia B or severe
haemophilia also had more chronic comorbidities (any), including pain
(13% and 8%) and depression (13% and 11%) compared to those with
haemophilia A or moderate haemophilia (pain, 3% and 5%; depression,
6% each, respectively).
3.1 Relative importance given to gene therapy
attributes
In the total sample analysis, participants indicated that the ‘effect
on overall bleeding rate’ held the greatest relative importance of all
gene therapy attributes (31%), followed closely by dose frequency
and durability (26%; Figure 1). Uncertainty regarding potential safety
issues and the impact on daily life were weighted somewhat similarly
to each other (17% and 11%, respectively) as secondary priorities
overall and across analysis subgroups. Relative attribute importance
was generally consistent across the subgroup analyses by haemophilia
type (Figure 2) and severity (Figure 3), where reduced annual bleeds
and treatment administration frequency/durability were given the
greatest relative importance overall.
Some notable differences were observed between subgroups. Par-
ticipants with haemophilia B gave dose frequency and durability the
greatest relative importance (35% as compared to 29% for effect
on bleeding rate). Frequency and durability relative attribute impor-
tance is much higher in haemophilia B participants than participants
with haemophilia A (35% vs. 23%; Figure 2). Participants with severe
haemophilia gave comparable to slightly higher relative importance to
dose frequency and durability (28%) as compared to effect on bleed-
ing rate (26%), whereas those with moderate haemophilia clearly gave
effect on bleeding the greatest relative importance (35% for bleeding
rate vs. 28% for dose frequency and durability); Figure 3.
3.2 Patient preference weighting of gene therapy
attribute levels
Mean preference weights (MPW) from the regression model assessing
patient preferences between attribute levels for the total sample
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F IGURE 1 Relative importance given to gene therapy attributes, all participants
F IGURE 2 Relative importance given to gene therapy attributes by haemophilia type
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Age, mean (SD), years 39.3 (13.8) 36.8 (12.3) 35.8 (11.4) 41.5 (14.7) 38.5 (13.4)
Sex, male, n (%) 120 (100) 63 (100) 97 (100) 86 (100) 183 (100)
Race, n (%)
White 89 (74) 48 (76) 75 (77) 62 (72) 137 (75)
Black/African-American 16 (13) 7 (11) 13 (13) 10 (12) 23 (13)
American Indian/Alaska Native 1 (1) 0 1 (1) 0 1 (1)
Asian 7 (6) 6 (10) 3 (3) 10 (12) 13 (7)
Hawaiian/Pacific Islander 1 (1) 0 1 (1) 0 1 (1)
Other 5 (4) 0 4 (4) 1 (1) 5 (3)
Not Stated 1 (1) 2 (3) 0 3 (4) 3 (2)
Employment Status, n (%)
Full-time employed 72 (60) 24 (38) 59 (61) 37 (43) 96 (53)
Part-time employed 16 (13) 16 (25) 24 (25) 8 (9) 32 (18)
Unemployed 13 (11) 7 (11) 6 (6) 14 (16) 20 (11)
Retired 9 (8) 7 (11) 3 (3) 13 (15) 16 (9)
Student 5 (4) 5 (8) 3 (3) 7 (8) 10 (6)
Other 5 (4) 4 (6) 2 (2) 7 (8) 9 (5)
Geographic Location, n (%)
Urban 59 (49) 31 (49) 60 (62) 30 (35) 90 (49)
Suburban 41 (34) 24 (38) 30 (31) 35 (41) 65 (36)
Rural 20 (17) 8 (13) 7 (7) 21 (24) 28 (15)
Chronic Comorbidities, n (%)
Any 75 (63) 49 (78) 60 (62) 64 (74) 124 (68)
Tiredness/fatigue 2 (1) 2 (3) 3 (3) 1 (1) 4 (2)
Pain 4 (3) 8 (13) 5 (5) 7 (8) 12 (7)
Insomnia 3 (3) 1 (2) 4 (4) 0 4 (2)
Anxiety/nerves 7 (6) 3 (5) 7 (7) 3 (4) 10 (6)
Depression 7 (6) 8 (13) 6 (6) 9 (11) 15 (8)
Diabetes 3 (3) 1 (2) 3 (3) 1 (1) 4 (2)
Breathing problems 4 (3) 3 (5) 6 (6) 1 (1) 7 (4)
High blood pressure 15 (13) 10 (16) 12 (12) 13 (15) 25 (14)
Heart disease 2 (2) 1 (2) 1 (1) 2 (2) 3 (2)
Osteoarthritis 8 (7) 8 (13) 5 (5) 11 (13) 16 (9)
Stroke 1 (1) 2 (3) 3 (3) 0 3 (2)
Cancer 3 (3) 1 (2) 3 (3) 1 (1) 4 (2)
Other 16 (13) 1 (12 2 (2) 15 (17) 17 (9)
SD, standard deviation.
are presented in Table 3. Absolute differences between preference
weights indicate the relative weight participants ascribed to one
level versus the other. Within the attribute ‘effect on overall annual
bleeding rate,’ participants indicated a substantial difference between
having 0 versus 5 or more bleeds per year (MPW, 0.68 for 0 bleeds
per year vs. -0.93 for ≥5 bleeds per year; absolute difference, 1.61).
This was the greatest difference between preference weights across
all attribute levels, followed by the difference between treatment
administrationmultiple times perweek (MPW,−0.78) versus one-time
treatment with lifetime durability (MPW, 0.59; absolute difference,
1.37). The next biggest difference was shared by three level sets: the
effect on bleeding rate of 0 vs. 1 bleed per year, thinking and worrying
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F IGURE 3 Relative importance given to gene therapy attributes by haemophilia severity
about haemophilia or treatment on some vs. zero days (‘freedom’), and
whether or not factor therapy may be needed vs. generally not needed
(absolute differences between level sets were all 1.13). Alternatively,
the least relative weighting (or smallest absolute difference) was given
to the comparison of having to do some planning vs. no planning of
activities based on gene therapy requirements (MPW, 0.03 and 0.26,
respectively; absolute difference, 0.29). Across attributes, nearly
all levels were determined to be significant with the exception of
treatment administration every 1–4 weeks, some planning required
to undertake activities, thinking and worrying about haemophilia or
treatment some days, and if factor therapy may or may not be needed
depending on the situation (Table 3). In other words, the worst and best
possible levels were generally the most meaningful determinants of
patient preferences when a relatively neutral level was included. No
neutral or nonsignificant levels were observed for effect on bleeding
rate or uncertainty related to safety issues.
Preferenceweighting across subgroupswas generally similar to that
observed in the total sample (Appendix Tables A2-A5). All subgroups
had the greatest absolute differences between worst and best levels
for the effect on bleeding and dosing frequency/durability attributes.
Participants with severe haemophilia showed the greatest differences
between opposite levels for all attributes, most notably for the dif-
ference between multiple administrations per week (most frequent
administration; MPW, −1.32) and one-time treatment with lifetime
durability (least frequent administration; MPW, 0.97; absolute differ-
ence, 2.29), and for 0 vs.≥5bleeds per year (0.89 vs. -1.26, respectively;
absolute difference, 2.15; Table A5). Participants with haemophilia B
showed greater differences between the same dosing levels (most vs.
least frequent, 1.88) than for effect on bleeds (0 vs.≥5, 1.58; Table A3),
which was reversed for those with haemophilia A (1.23 between dos-
ing levels and 1.71 between bleeding rates; TableA2). Unlike other sub-
groups, none of the levels for the transformative/mental health impact
or post-gene therapy treatment requirement attributes were signifi-
cant for participants with haemophilia B ormoderate haemophilia.
4 DISCUSSION
This DCE study evaluated patient preferences for gene therapy
attributes among people with haemophilia. Overall, participants gave
the greatest importance to efficacy and administration attributes,
where the reduction of annual bleeding rates and the least amount of
treatment burden were shown to be clear, meaningful priorities from
the patient perspective. Uncertainty regarding potential safety issues
was a close secondary priority followed by impact on daily life and
mental health. We observed some differences between haemophilia
types and levels of severity, where those with haemophilia A or mod-
erate haemophilia tended to give more weight to reduced bleeding
than to dosing frequency/durability. People with haemophilia B clearly
gave the greatest relative importance to dosing frequency/durability,
but those with severe haemophilia expressed the greatest net dif-
ference in preference weights between the most and least frequent
dosing scenarios (net difference, 2.29 and 1.88 for severe and mod-
erate haemophilia, respectively). These findings can inform shared
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Dose frequency and durability
Administrationmultiple times per week −0.78 (−0.95,−0.61) 0.54 (0.36, 0.73) <0.01**
Administration every 1–4weeks 0.02 (−0.11, 0.15) 0.23 (−0.03, 0.5) 0.80
One-time treatment - 10 year durability then return to standard of care at that current time 0.17 (0.04, 0.31) 0.32 (0.1, 0.54) 0.01*
One-time treatment - lifetime durability 0.59 (0.42, 0.76) – <0.01**
Effect on overall annual bleeding rate
5 ormore bleeds per year −0.93 (−1.11,−0.74) 0.63 (0.46, 0.81) <0.01**
3 bleeds per year −0.21 (−0.34,−0.08) 0.25 (−0.03, 0.53) <0.01**
1 bleed per year 0.45 (0.32, 0.58) 0.03 (−0.22, 0.28) <0.01**
0 bleeds per year 0.68 (0.51, 0.86) – <0.01**
Uncertainty regarding short-term or long-term significant safety issues
Potential risk of short-termAND long-term significant safety issue −0.34 (−0.49,−0.19) 0.54 (0.37, 0.7) <0.01**
Potential risk of long-term significant safety issue −0.34 (−0.47,−0.21) −0.17 (−0.54, 0.21) <0.01**
Potential risk of short-term significant safety issue 0.14 (0, 0.27) −0.07 (−0.36, 0.22) 0.04*
Very low risk of short-termOR long-term significant safety issue 0.55 (0.39, 0.71) – <0.01**
Impact on activity of daily life/physical activity
A lot of planning required to undertake daily activities, travel, and physical activity −0.3 (−0.41,−0.18) 0.36 (0.22, 0.51) <0.01**
Some planning required to undertake daily activities, travel, and physical activity 0.03 (−0.07, 0.13) 0.11 (−0.16, 0.38) 0.53
Freedom to undertake daily activities, travel, and physical activity 0.26 (0.15, 0.38) – <0.01**
Transformative/mental health impact
Thinking andworrying about haemophilia or the treatmentmost days −0.23 (−0.33,−0.13) −0.02 (−0.32, 0.27) <0.01**
Thinking andworrying about haemophilia or the treatment some days 0.1 (−0.01, 0.2) −0.22 (−0.39,−0.05) 0.08
Freedom from thinking andworrying about haemophilia or the treatmentmost days 0.13 (0.03, 0.23) – 0.01*
Post treatment, possibility to undergominor surgery without need for factor therapy
Factor therapy always needed −0.2 (−0.31,−0.1) 0.35 (0.21, 0.49) <0.01**
Factor therapymay ormay not be needed, depending on the situation 0.03 (−0.07, 0.13) 0.22 (0.05, 0.4) 0.60
Factor therapy generally NOT needed 0.18 (0.06, 0.29) – <0.01**
SD, standard deviation.
*Significant at the P< 0.05 level; **Significant at P< 0.01 level.
aSign of the standard deviation is irrelevant and should be interpreted as being positive.
decision-making in the clinical setting as well as health technology
assessments that value the patient perspective in achieving optimal
health outcomes for people with this lifelong condition.
As clinical development of gene therapies is ongoing, there is some
patient preference research emerging. Sun and colleagues conducted
a DCE among 95 men in the US with moderate or severe haemophilia
A who had been receiving prophylaxis for a mean of 14 years.17 Test
attributes included dosing frequency, place of administration (home
vs. clinic), out-of-pocket cost, chance of a breakthrough bleed in 1 year,
factor VIII level, risk of inhibitor development, and risk of serious
side effects. Participants gave the greatest relative importance to fre-
quency and route of administration (30%), out-of-pocket cost (24%),
and place of administration (17%), followed by chance of breakthrough
bleed within 1 year (13%). The attributes and levels were different
from our study, where dosing frequency levels were one-time vs. every
other day (our most disparate levels were one-time vs. daily), though
relative importance was not dissimilar (our haemophilia A participants
indicated 23% relative importance to dose frequency). The significant
out-of-pocket cost attribute reportedby Sunet alwas $0 vs. a one-time
$3000 payment, eliciting a perhaps understandable preference for the
null cost burden to the patient. Further analysis of levels or subgroups
with moderate vs. severe disease was not available at the time of this
writing. van Overbeeke and colleagues evaluated minimal acceptable
benefits required to switch from prophylaxis to gene therapy among
117 Belgian patients, predominantly with haemophilia A (84%).24 The
qualitative research used to determine the final attributes for testing
identified effect on annual bleeding rate, factor level, uncertainty of
long-term risks, impact on daily life, and probability to stop prophylaxis
as the attributes of greatest concern, similar to those determined
most relevant for our DCE.25 Treatment attributes ultimately included
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annual bleeding rate, chance to stop prophylaxis, quality of life, and
time that side effects have been studied. In the context of preference
heterogeneity reported to be driven by demographic and clinical
characteristics, participants tended to prefer gene therapy over
prophylaxis. Our study was able to procure the largest sample size
of the gene therapy preference studies published to date. We were
also able to include patients with haemophilia A or B, and moderate or
severe haemophilia, using a sophisticated DCE approach with relative
attribute importance and quantifiable attribute-level assessments.
This work represents a patient-focused approach to understanding
treatment preferences in order to translate the perspectives of peo-
plewith haemophilia into practice. This collaborationwith theNational
Haemophilia Foundation’s Community Voices in Research (NHF CVR)
initiative represents a step forward in the ability to access and con-
sider community-based points of view from the primary stakeholders
in haemophilia care: the patients themselves. While the NHF CVR is
not itself a research-driven enterprise, it was designed to serve and
advance research efforts, among other purposes, that are driven by
patient-reported outcomes. As the study only recruited via patient
panels it may not be truly representative of the haemophilia commu-
nity as it is only receiving responses frompeoplewith haemophilia who
are actively engaged in research. Future research could aim to broaden
the recruitment strategy not only to patient panels, to see if the find-
ings remain the same regarding the patients’ preferences.
People with haemophilia endure a lifelong disease and treatment
burden, particularly those with moderate or severe disease, and
understandably place substantial value on both the efficacy of treat-
ment and its impact on their daily lives. Our DCE has shown that the
potential of stable long-term factor VIII/IX expression and to eliminate
the need for factor replacement therapy offered by gene therapy is
prioritised by patients when improvements in efficacy and treatment
burden are possible.26,27 We employed a tested, reliable approach
to quantifying the patient perspective on these decision points, with
a rigorous qualitative evaluation of our DCE instrument. It should
be noted that participants were volunteers and may have differed
from the broader population of people with haemophilia in the US
or beyond, or from certain subgroups. This DCE used hypothetical
scenarios to elicit patient preferences, a common potential limitation
to choice-based studies, though our work to qualitatively assess, test,
and refine the DCE instrument was based on a solid existing evidence
base and personal interviewswith experts and patients. Interpretation
of the information presented in the DCE may have varied between
individual based upon the level of knowledge upon potential long-
term and short-term safety issues. Finally, other unmeasured patient
characteristics may have contributed to reported preferences, such
as those related to the patients’ overall level of disease and treatment
burden or other social or cultural variables.
5 CONCLUSION
This patient-centric evaluation of current and novel haemophilia treat-
ments showed the prominence of annual bleeding rate and reduced
treatment burden in the perspectives of people with haemophilia.
Key differences provided more granular insight into self-reported
preferences than has been reported previously, as participants with
haemophilia B gave the greatest relative importance to dosing
frequency/durability and those with haemophilia A or moderate
haemophilia gave more weight to reduced bleeding. The inherent
uncertainty related to potential safety issues and the impact on daily
lifewere found to be secondary priorities regardless of type or severity
of disease. This work has important implications for point of care and
health policy decisions seeking to improve health equity for patients
with haemophilia, which necessarily requires that the patient perspec-
tive be considered in treatment decisions. Incorporating patient prior-
ities into patient- and population-level decisions will also optimise the
chances of achieving the best possible outcomes offered by therapeu-
tic advances.
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F IGURE A1 Discrete Choice Experiment Example – Dominated Scenario
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Dose frequency and durability
Administrationmultiple times per week −0.73 (−0.94,−0.52) 0.53 (0.27, 0.78) <0.01**
Administration every 1–4weeks 0.13 (−0.03, 0.30) 0.23 (−0.11, 0.57) 0.12
One-time treatment - 10 year durability then return to standard of care at that current time 0.10 (−0.08, 0.27) 0.33 (0.03, 0.63) 0.27
One-time treatment - lifetime durability 0.50 (0.29, 0.71) – <0.01**
Effect on overall annual bleeding rate
5 ormore bleeds per year −0.96 (−1.21,−0.72) 0.57 (0.34, 0.80) <0.01**
3 bleeds per year −0.17 (−0.35, 0.01) 0.43 (0.15, 0.72) 0.06
1 bleed per year 0.39 (0.22, 0.55) −0.15 (−0.46, 0.16) <0.01**
0 bleeds per year 0.75 (0.50, 0.99) – <0.01**
Uncertainty regarding short-term or long-term significant safety issues
Potential risk of short-termAND long-term significant safety issue −0.33 (−0.50,−0.15) 0.41 (0.15, 0.67) <0.01**
Potential risk of long-term significant safety issue −0.35 (−0.53,−0.17) 0.37 (0.10, 0.64) <0.01**
Potential risk of short-term significant safety issue 0.09 (−0.08, 0.25) 0.12 (−0.40, 0.64) 0.30
Very low risk of short-termOR long-term significant safety issue 0.59 (0.38, 0.80) – <0.01**
Impact on activity of daily life/physical activity
A lot of planning required to undertake daily activities, travel, and physical activity −0.31 (−0.46,−0.17) 0.41 (0.22, 0.6) <0.01**
Some planning required to undertake daily activities, travel, and physical activity 0.06 (−0.07, 0.18) 0.15 (−0.16, 0.46) 0.39
Freedom to undertake daily activities, travel, and physical activity 0.26 (0.11, 0.41) – <0.01**
Transformative/mental health impact
Thinking andworrying about haemophilia or the treatmentmost days −0.30 (−0.43,−0.17) 0.01 (−0.35, 0.37) <0.01**
Thinking andworrying about haemophilia or the treatment some days 0.10 (−0.04, 0.23) 0.21 (−0.02, 0.44) 0.16
Freedom from thinking andworrying about haemophilia or the treatmentmost days 0.20 (0.07, 0.33) – <0.01**
Post treatment, possibility to undergominor surgery without need for factor therapy
Factor therapy always needed −0.23 (−0.38,−0.09) 0.40 (0.21, 0.58) <0.01**
Factor therapymay ormay not be needed, depending on the situation 0.03 (−0.10, 0.17) 0.34 (0.12, 0.56) 0.65
Factor therapy generally NOT needed 0.20 (0.05, 0.36) – 0.01*
SD, standard deviation.
*Significant at the P< 0.05 level; **Significant at P< 0.01 level.
aSign of the standard deviation is irrelevant and should be interpreted as being positive.
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Dose frequency and durability
Administrationmultiple times per week −1.00 (−1.34,−0.66) 0.57 (0.21, 0.93) <0.01**
Administration every 1–4weeks −0.25 (−0.49, 0) 0.18 (−0.35, 0.72) 0.05
One-time treatment - 10 year durability then return to standard of care at that current time 0.37 (0.11, 0.64) 0.43 (0.08, 0.78) <0.01**
One-time treatment - lifetime durability 0.88 (0.54, 1.22) – <0.01**
Effect on overall annual bleeding rate
5 ormore bleeds per year −0.96 (−1.31,−0.61) 0.75 (0.42, 1.07) <0.01**
3 bleeds per year −0.29 (−0.51,−0.06) 0.05 (−0.29, 0.39) 0.01*
1 bleed per year 0.63 (0.37, 0.89) −0.14 (−0.52, 0.25) <0.01**
0 bleeds per year 0.62 (0.31, 0.93) – <0.01**
Uncertainty regarding short-term or long-term significant safety issues
Potential risk of short-termAND long-term significant safety issue −0.39 (−0.71,−0.07) 0.84 (0.52, 1.15) 0.02*
Potential risk of long-term significant safety issue −0.38 (−0.62,−0.14) 0.14 (−0.31, 0.58) <0.01**
Potential risk of short-term significant safety issue 0.27 (0.02, 0.51) −0.02 (−0.62, 0.58) 0.03*
Very low risk of short-termOR long-term significant safety issue 0.51 (0.18, 0.84) – <0.01**
Impact on activity of daily life/physical activity
A lot of planning required to undertake daily activities, travel, and physical activity −0.26 (−0.47,−0.06) 0.43 (0.14, 0.72) 0.01*
Some planning required to undertake daily activities, travel, and physical activity −0.02 (−0.19, 0.16) 0.11 (−0.29, 0.50) 0.86
Freedom to undertake daily activities, travel, and physical activity 0.28 (0.07, 0.49) – <0.01**
Transformative/mental health impact
Thinking andworrying about haemophilia or the treatmentmost days −0.09 (−0.27, 0.09) −0.09 (−0.41, 0.22) 0.34
Thinking andworrying about haemophilia or the treatment some days 0.12 (−0.08, 0.32) 0.31 (0.04, 0.58) 0.24
Freedom from thinking andworrying about haemophilia or the treatmentmost days −0.03 (−0.22, 0.16) – 0.74
Post treatment, possibility to undergominor surgery without need for factor therapy
Factor therapy always needed −0.15 (−0.32, 0.03) 0.16 (−0.21, 0.53) 0.11
Factor therapymay ormay not be needed, depending on the situation −0.01 (−0.18, 0.17) 0.11 (−0.21, 0.43) 0.93
Factor therapy generally NOT needed 0.15 (−0.04, 0.35) – 0.11
SD, standard deviation.
*Significant at the P< 0.05 level; **Significant at P< 0.01 level.
aSign of the standard deviation is irrelevant and should be interpreted as being positive.
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Dose frequency and durability
Administrationmultiple times per week −0.62 (−0.82,−0.42) 0.33 (0.07, 0.60) <0.01**
Administration every 1–4weeks −0.08 (−0.25, 0.09) 0.12 (−0.27, 0.51) 0.34
One-time treatment - 10 year durability then return to standard of care at that current time 0.18 (0, 0.36) −0.32 (−0.58,−0.07) 0.05
One-time treatment - lifetime durability 0.52 (0.31, 0.73) – <0.01**
Effect on overall annual bleeding rate
5 ormore bleeds per year −0.84 (−1.08,−0.60) 0.59 (0.37, 0.81) <0.01**
3 bleeds per year −0.25 (−0.43,−0.07) −0.27 (−0.58, 0.04) <0.01**
1 bleed per year 0.48 (0.31, 0.65) −0.03 (−0.29, 0.22) <0.01**
0 bleeds per year 0.61 (0.39, 0.84) – <0.01**
Uncertainty regarding short-term or long-term significant safety issues
Potential risk of short-termAND long-term significant safety issue −0.32 (−0.49,−0.16) 0.27 (0.01, 0.54) <0.01**
Potential risk of long-term significant safety issue −0.22 (−0.39,−0.05) 0.16 (−0.32, 0.64) 0.01*
Potential risk of short-term significant safety issue 0.09 (−0.07, 0.25) 0.03 (−0.6, 0.67) 0.28
Very low risk of short-termOR long-term significant safety issue 0.45 (0.27, 0.64) – <0.01**
Impact on activity of daily life/physical activity
A lot of planning required to undertake daily activities, travel, and physical activity −0.18 (−0.32,−0.04) 0.33 (0.15, 0.52) 0.01*
Some planning required to undertake daily activities, travel, and physical activity −0.02 (−0.15, 0.11) 0.19 (−0.05, 0.43) 0.71
Freedom to undertake daily activities, travel, and physical activity 0.20 (0.05, 0.35) – <0.01**
Transformative/mental health impact
Thinking andworrying about haemophilia or the treatmentmost days −0.10 (−0.23, 0.02) 0.04 (−0.17, 0.25) 0.10
Thinking andworrying about haemophilia or the treatment some days 0.02 (−0.11, 0.15) −0.15 (−0.45, 0.15) 0.79
Freedom from thinking andworrying about haemophilia or the treatmentmost days 0.08 (−0.04, 0.21) – 0.19
Post treatment, possibility to undergominor surgery without need for factor therapy
Factor therapy always needed −0.10 (−0.24, 0.05) 0.39 (0.21, 0.57) 0.19
Factor therapymay ormay not be needed, depending on the situation 0 (−0.13, 0.12) −0.12 (−0.38, 0.14) 0.96
Factor therapy generally NOT needed 0.10 (−0.05, 0.25) – 0.18
SD, standard deviation.
*Significant at the P< 0.05 level; **Significant at P< 0.01 level.
aSign of the standard deviation is irrelevant and should be interpreted as being positive.
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Dose frequency and durability
Administrationmultiple times per week −1.32 (−1.78,−0.86) 1.13 (0.71, 1.55) <0.01**
Administration every 1–4weeks 0.14 (−0.10, 0.38) −0.35 (−0.87, 0.17) 0.26
One-time treatment - 10 year durability then return to standard of care at that current time 0.21 (−0.05, 0.46) 0.51 (0.19, 0.84) 0.12
One-time treatment - lifetime durability 0.97 (0.55, 1.40) – <0.01**
Effect on overall annual bleeding rate
5 ormore bleeds per year −1.26 (−1.64,−0.89) 0.86 (0.48, 1.24) <0.01**
3 bleeds per year −0.21 (−0.45, 0.04) −0.30 (−0.69, 0.10) 0.10
1 bleed per year 0.58 (0.30, 0.86) 0.28 (−0.08, 0.64) <0.01**
0 bleeds per year 0.89 (0.56, 1.22) – <0.01**
Uncertainty regarding short-term or long-term significant safety issues
Potential risk of short-termAND long-term significant safety issue −0.42 (−0.75,−0.10) 1.02 (0.67, 1.36) 0.01*
Potential risk of long-term significant safety issue −0.63 (−0.88,−0.38) 0.03 (−0.38, 0.44) <0.01**
Potential risk of short-term significant safety issue 0.26 (0, 0.52) −0.07 (−0.43, 0.3) 0.05
Very low risk of short-termOR long-term significant safety issue 0.79 (0.45, 1.14) – <0.01**
Impact on activity of daily life/physical activity
A lot of planning required to undertake daily activities, travel, and physical activity −0.49 (−0.72,−0.27) 0.51 (0.23, 0.80) <0.01**
Some planning required to undertake daily activities, travel, and physical activity 0.08 (−0.10, 0.26) 0.13 (−0.16, 0.41) 0.39
Freedom to undertake daily activities, travel, and physical activity 0.42 (0.20, 0.63) – <0.01**
Transformative/mental health impact
Thinking andworrying about haemophilia or the treatmentmost days −0.45 (−0.65,−0.24) −0.32 (−0.60,−0.04) <0.01**
Thinking andworrying about haemophilia or the treatment some days 0.26 (0.05, 0.46) 0.37 (0.09, 0.66) 0.01*
Freedom from thinking andworrying about haemophilia or the treatmentmost days 0.19 (−0.01, 0.39) – 0.07
Post treatment, possibility to undergominor surgery without need for factor therapy
Factor therapy always needed −0.41 (−0.60,−0.22) 0.28 (−0.04, 0.60) <0.01**
Factor therapymay ormay not be needed, depending on the situation 0.04 (−0.18, 0.25) 0.49 (0.24, 0.74) 0.74
Factor therapy generally NOT needed 0.38 (0.13, 0.62) – <0.01**
SD, standard deviation.
*Significant at the P< 0.05 level; **Significant at P< 0.01 level.
aSign of the standard deviation is irrelevant and should be interpreted as being positive.
